Introduction
============

Coronary heart disease (CHD) is a major public health problem ([@b1-etm-0-0-8597]). In 2016, the American Heart Association reported that there were 400,000 deaths due to CHD each year in the United States, and that the number of new cases has increased to 785,000([@b2-etm-0-0-8597]). Dual antiplatelet therapy (DAPT) is a cornerstone treatment for arterial coronary disease, and second line for the prevention of cardiovascular and cerebrovascular events. Therefore, endoscopists are encountering increasing numbers of patients on DAPT.

Post-polypectomy bleeding (PPB) is the most common complication of colonoscopy with polypectomy, ranging in prevalence from 0.6-6.1% ([@b3-etm-0-0-8597]). Antiplatelet agents such as the thienopyridines and aspirin have been used widely to decrease thrombotic events, particularly in patients who have had coronary stents, peripheral stents for vascular disease, myocardial infarctions and cerebrovascular events ([@b4-etm-0-0-8597]). For patients on antiplatelet therapy undergoing polypectomy, the management of perioperative therapy is a common clinical dilemma ([@b5-etm-0-0-8597]). The physician needs to weigh the increased risk of PPB against the thrombotic risk caused by discontinuation of the antiplatelet agents. Although the interruption of clopidogrel decreases PPB, it has been associated with higher mortality rates, due to complications such as stent thrombosis, myocardial infarction and stroke ([@b6-etm-0-0-8597]). Nonetheless, there is no consensus on how the risk of PPB and of thrombotic events should be balanced, resulting in considerable variability in current clinical practice ([@b7-etm-0-0-8597]). A retrospective study discovered that the incidence of delayed PPB within 30 days following polypectomy was significantly higher inpatients on clopidogrel and concomitant aspirin/nonsteroidal anti-inflammatory drugs ([@b6-etm-0-0-8597]). However, another study showed that the delayed PPB rate inpatients on clopidogrel was \<1%, which was within acceptable ranges reported for the general population not undergoing clopidogrel therapy. There was no significant difference in the PPB rates between patients receiving and not receiving clopidogrel ([@b8-etm-0-0-8597]). However, a prospective study demonstrated that the rate of immediate PPB (persistent bleeding observed at the time of polypectomy) and delayed PPB was significantly higher in patients on uninterrupted thienopyridines ([@b9-etm-0-0-8597]). Moreover, two meta-analyses both demonstrated that continued clopidogrel therapy increased the risk of delayed PPB and suggested deferring elective polypectomy until it was safe to terminate clopidogrel therapy ([@b10-etm-0-0-8597],[@b11-etm-0-0-8597]). Therefore, the current guidelines recommend temporary cessation of thienopyridine agents prior to high-risk endoscopic procedures, such as polypectomy, but uninterrupted thienopyridines for low-risk endoscopic procedures, such as biopsy ([@b12-etm-0-0-8597],[@b13-etm-0-0-8597]). However, a recent prospective observational study showed that the risk of early major cardiac adverse events was increased to 7.04 following the cessation of antiplatelet agents, and was highest in the first 7 days ([@b14-etm-0-0-8597]). In addition, a meta-analysis revealed a notably high risk of major cardiac adverse events following the interruption of antiplatelet therapy in patients with coronary stents \[odds rate (OR), 89.78; 95% confidence interval (CI), 29.9-269.6\] ([@b15-etm-0-0-8597]). Interestingly, the most recent prospective study reported that patients on continued clopidogrel had a slightly higher incidence rate of immediate and delayed PPB compared with those on discontinued clopidogrel; however, this difference was not statistically significant ([@b16-etm-0-0-8597]). This observation could be challenged with guidelines and by most gastroenterologists ([@b17-etm-0-0-8597]).

Overall, the management of medications in the periprocedural period lacks sufficient data and guidelines ([@b18-etm-0-0-8597]). Thus, a meta-analysis was performed to assess the risks of immediate and delayed PPB associated with the continued use of clopidogrel during colonoscopy and polypectomy, based on the available medical literature.

Materials and methods
=====================

### Search strategy

A systemic search was conducted via the PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), Web of Science (<http://webofscience.com>) and Cochrane library (<https://www.cochranelibrary.com/>) databases to identify available publications, in order to compare PPB rates in patients on continued or discontinued clopidogrel. The keywords used are listed: 'clopidogrel or thienopyridine' and 'colonoscopy or polypectomy'. A manual search for additional relevant publications was also conducted by screening the included studies. This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines ([@b19-etm-0-0-8597]). This study was registered in PROSPERO (no. CRD42018118325).

### Inclusion and exclusion criteria

The inclusion criteria were as follows: i) Randomized controlled trials (RCTs) and retrospective cohort or case-control studies reported in English; ii) patients on continued clopidogrel and non-clopidogrel undergoing colonoscopic polypectomy; iii) defining immediate PPB as bleeding at the time of polypectomy; iv) defining delayed PPB as bleeding occurring as late as 4 weeks or 30 days after the procedure \[in the present study, delayed PPB was considered to be clinically significant delayed PPB, which included hemodynamic instability and a hemoglobin drop of at least 2 g/l, hospitalization, packed red cell transfusion, endoscopy intervention or surgery ([@b20-etm-0-0-8597])\]; v) patients receiving concomitant aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs); and vi) patients who had had their clopidogrel discontinued for \>5 days were included and placed in the non-clopidogrel group. The exclusion criteria were as follows: i) Patients receiving concomitant anticoagulant medication, such as warfarin and heparin; and ii) patients who were not taking clopidogrel on the day of the polypectomy, or in whom polypectomy was not performed.

### Outcomes

The primary outcome was the incidence of colonoscopic PPB inpatients on continued clopidogrel and those who received interrupted antiplatelet therapy. The secondary outcomes were immediate PPB, delayed PPB and serious cardio-thrombotic events.

### Quality assessment

Quality assessment was independently carried out by three reviewers, according to the Newcastle-Ottawa Scale (NOS) ([@b21-etm-0-0-8597]) for retrospective case-control studies and the Jadad Scale ([@b22-etm-0-0-8597]) for prospective controlled trials. Total scores of 0-3, 4-5 and 6-8 corresponded to low, moderate and high quality in the retrospective case-control studies, respectively. Good trials had a score of 3-5, whereas total scores of 0-2 corresponded to poor trials in RCTs.

### Statistical analysis

All pooled data were analyzed with Review Manager 5.3 software (Cochrane Informatics and Knowledge Management Department, <http://tech.cochrane.org/revman/download>). Dichotomous variables were expressed as a risk ratio (RR) with a 95% CI. The χ^2^ test and I^2^ test were used to test heterogeneity, and a value of 25, 50 or 75% suggested low, moderate and high heterogeneity, respectively. The random-effects model was used for high heterogeneity; otherwise, the fixed-effects model was used ([@b23-etm-0-0-8597]). A two-sided P\<0.05 was considered to indicate a statistically significant difference. A funnel plot for colonoscopic PPB, immediate PPB and delayed PPB was generated to assess the body of literature for publication bias.

Results
=======

### Search results

A total of 42 studies were identified by the present search strategy, of which 39 were complete articles and three were abstracts. A total of 10 studies, including two meta-analyses, five complete articles and three abstracts that assessed PPB rates in patients on continued clopidogrel met the inclusion criteria; however, two abstracts defined delayed PPB as bleeding within 15 days after polypectomy, one complete article investigated only the bleeding risk of polypectomy in patients on clopidogrel, and two meta-analysis articles were excluded. In total, four complete articles and one abstract, containing two prospective controlled trials, and three retrospective case-control studies were included in the present meta-analysis ([Fig. 1](#f1-etm-0-0-8597){ref-type="fig"}).

### Characteristics of included studies

Five eligible studies ([Table I](#tI-etm-0-0-8597){ref-type="table"}) reported on 7,275 patients undergoing colonoscopy with polypectomy, of whom 655 patients (9.0%) were in the continued clopidogrel group and 6,620 patients (91%) were in the control group. In the study by Singh *et al* ([@b6-etm-0-0-8597]), which included 142 patients on continued clopidogrel and 1,243 patients not on clopidogrel, 54% of patients on continued clopidogrel also received concomitant aspirin treatment, and 32% of patients in the control group were taking aspirin. The rate of immediate PPB was similar in both groups; however, the rate of delayed PPB was higher in the continued clopidogrel group. The study by Grossman *et al* ([@b24-etm-0-0-8597]) was published as a conference abstract, which included 70 patients taking clopidogrel only and 3,121 patients on non-clopidogrel therapy. Patients on continued clopidogrel demonstrated increased risk of both immediate and delayed PPB. In the study by Feagins *et al* ([@b8-etm-0-0-8597]), containing 118 patients on clopidogrel and 1,849 patients not taking clopidogrel, concomitant aspirin use was prevalent in 78.8% of clopidogrel users compared with 27.9% of the control group. It was found that continued clopidogrel did not increase the rate of delayed PPB. The Feagins *et al* ([@b9-etm-0-0-8597]) study was a prospective trial including 219 patients receiving clopidogrel and 297 patients not receiving clopidogrel; most of the patients were receiving concomitant aspirin. It was demonstrated that only delayed PPB was elevated in the continued clopidogrel group. The study by Chan *et al* ([@b16-etm-0-0-8597]) was also a prospective trial, including 226 patients treated with clopidogrel alone or in combination with other anti-platelet medications (e.g. aspirin). Of these patients, 106 received uninterrupted clopidogrel and 110 received a 7-day interruption of clopidogrel. It was demonstrated that continued clopidogrel resulted in a small increase in immediate and delayed PPB; however, this difference was not statistically significant.

### Quality of included studies

Jadad scores and Newcastle-Ottawa scores for 2 RCTs and 3 retrospective case-control studies are shown in Tables II and III, respectively. All studies were scored as high quality.

### Colonoscopic PPB

A total of five studies met the inclusion criteria and were eventually selected for analysis. The pooled PPB rate was calculated using a fixed-effect model, as the heterogeneity was not significantly different among these studies (P=0.47; I^2^, 0%; [Fig. 2](#f2-etm-0-0-8597){ref-type="fig"}). Based on the data of 655 patients on continued clopidogrel (49/655) and 6,620 patients in the control group (139/6,620), the RR of PPB increased to 1.96 in the continued clopidogrel group (P=0.0003; 95%CI, 1.36-2.83; [Fig. 2](#f2-etm-0-0-8597){ref-type="fig"}).

### Immediate PPB

Four studies measured immediate PPB, where a total of 31/537 patients on continued clopidogrel and 84/4,771 patients not receiving clopidogrel developed immediate PPB. The immediate PPB rate was slightly higher in the continued clopidogrel group (5.77%) compared with the control group (1.77%); however, this was not significant (fixed-effect model; P=0.06; RR, 1.57; 95%CI 0.98-2.51) and there was no heterogeneity (P=0.49; I^2^, 0%; [Fig. 3](#f3-etm-0-0-8597){ref-type="fig"}).

### Delayed PPB

A total of five studies reported delayed PPB. As shown in [Fig. 4](#f4-etm-0-0-8597){ref-type="fig"}, the pooled RR of the delayed PPB was increased to 3.10 (P=0.0008; 95%CI, 1.60-5.98), based on a fixed-effects model with no heterogeneity (P=0.43; I^2^, 0%).

### Serious cardio-thrombotic events

Only two studies assessed serious cardio-thrombotic events, which were observed in 3 out of 325 patients on clopidogrel (0.92%) compared with 4 out of 407 patients (0.98%) in the control group, with a non-significant pooled RR of 0.78 within 30 days (P=0.74; 95%CI, 0.18-3.40; [Fig. 5](#f5-etm-0-0-8597){ref-type="fig"}).

### Publication bias

There was no publication bias in colonoscopic PPB, immediate PPB and delayed PPB demonstrated by funnel plot analysis (P=0.797, P=0.816 and P=0.720, respectively; [Fig. 6](#f6-etm-0-0-8597){ref-type="fig"}).

Discussion
==========

Colorectal cancer (CRC) ranks third in terms of incidence but second in terms of mortality of all cancer types in the USA ([@b25-etm-0-0-8597]). It is estimated that there will be 140,250 new cases and 50,630 deaths in the United States in 2018([@b25-etm-0-0-8597]). Currently, the preferred modality for detection and prevention of CRC is an endoscopic procedure every 10 years, beginning at 50 years of age. However, most patients with known heart disease are over 50 years and are taking clopidogrel and other thienopyridines ([@b26-etm-0-0-8597]). Active antiplatelet therapy complicates colorectal detection by increasing the risk of complications, including PPB. Interruption of antiplatelet therapy may pose a high thrombosis risk and be associated with high mortality inpatients during endoscopic procedures, particularly polypectomy ([@b27-etm-0-0-8597]). In the present study, a meta-analysis was performed to estimate the rate of PPB in patients on continued clopidogrel.

The results of the present study demonstrated that continued clopidogrel increased the occurrence of delayed PPB, which is consistent with the current guidelines and previously published meta-analyses ([@b10-etm-0-0-8597],[@b11-etm-0-0-8597]). However, one published meta-analysis included only one prospective controlled trial and four retrospective case-control studies, and the definition of delayed PPB was inconsistent between these studies; four studies defined delayed PPB as bleeding within 4 weeks, whereas another study defined it as bleeding within 15 days, indeed, this inconsistency may affect the accuracy of the results and publication bias was not assessed ([@b10-etm-0-0-8597]). Another published meta-analysis included only two retrospective case-control studies; however, one study defined delayed PPB as bleeding within 15 days after polypectomy ([@b11-etm-0-0-8597]). In the present meta-analysis, two prospective controlled trials and three retrospective case-control studies were included, delayed PPB was defined as bleeding within 4 weeks or 30 days after post-polypectomy, and all patients who were receiving concomitant aspirin or other NSAIDs were included. Therefore, the present study evaluated the rate of PPB more rigorously. To the best of our knowledge, the present study is the first to demonstrate that continued clopidogrel therapy did not increase the number of serious cardio-thrombotic events.

A number of limitations remain in this meta-analysis. The first major limitation was the small number of RCTs, which may limit the statistical power of these findings. The present study demonstrated that continued clopidogrel therapy did not increase the number of serious cardio-thrombotic events, which was inconsistent with previous publications ([@b14-etm-0-0-8597],[@b15-etm-0-0-8597]), and thus required further confirmation. Secondly, the present study included three retrospective case-control studies, which can lead to selection bias. Thirdly, patient-associated factors contributing to PPB have been described, such as increased age ([@b28-etm-0-0-8597]), chronic renal disease ([@b28-etm-0-0-8597]), coronary artery disease (CAD) ([@b29-etm-0-0-8597]) and hypertension ([@b30-etm-0-0-8597]). In the present study, the patients on clopidogrel were older and had more comorbidities than the non-clopidogrel users, and this difference contributed to elevated rates of PPB in the continued clopidogrel group. Furthermore, polyp- and procedure-associated risk factors, such as polyp size ([@b31-etm-0-0-8597],[@b32-etm-0-0-8597]), polyp location ([@b31-etm-0-0-8597],[@b32-etm-0-0-8597]), the number of removed polyps ([@b33-etm-0-0-8597]), endoscopists experience ([@b32-etm-0-0-8597],[@b34-etm-0-0-8597]) and removal modality ([@b28-etm-0-0-8597]), were associated with the rate of PPB. However, these factors were not considered in the present study, due to limited data. Moreover, because endoscopists were not blinded during polypectomy in the study, prophylactic clip placement was routinely applied after polypectomy, which could decrease the PPB rate in the clopidogrel group ([@b18-etm-0-0-8597],[@b28-etm-0-0-8597]). Parikh *et al* ([@b35-etm-0-0-8597]) suggested that the prophylactic clip placement may be cost-effective for patients on clopidogrel therapy following polypectomy. However, 2 randomized controlled trials and 1 meta-analysis showed that preventative clip placement did not significantly benefit patients receiving thienopyridines ([@b36-etm-0-0-8597]). The present study does not discriminate the effect of concomitant aspirin or NSAID therapy. A meta-analysis showed that the rate of delayed PPB was elevated in patients on clopidogrel therapy, who were also receiving other anti-platelet medicines, compared with non-clopidogrel users ([@b11-etm-0-0-8597]). However, a retrospective case control study did not yield similar results ([@b39-etm-0-0-8597]). Finally, whether resuming antiplatelet agents may increase the rate of delayed PPB after polypectomy remains in question. A retrospective case control study showed that resuming the intake of antithrombotics earlier (within 1 week) can elevate the rate of delayed PPB ([@b39-etm-0-0-8597]). At present, little data have been published on this subject.

Despite these limitations, the present study also offers some important implications for clinical practice. The effect of continued clopidogrel therapy on serious cardio-thrombotic events, compared with discontinued clopidogrel, requires further study. However, the present study showed that the rates of immediate PPB and delayed PPB in patients on continued clopidogrel were 5.77 and 2.78%, respectively. Moreover, although the rate of PPB was significantly higher in the continued clopidogrel group, it was controlled adequately by blood transfusions and repeat colonoscopy, and no patients died or required surgery. However, these treatments could also increase the economic burden of medical health care. The findings of the present study suggested that endoscopists should prepare to prevent bleeding in the perioperative period, in the event that polypectomy cannot be reasonably postponed and clopidogrel therapy could not be interrupted.
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###### 

Characteristics of included studies.

  Author, year             Study type                                          Patients with polypectomy, n   Clopidegrol and ASA/NSAIDs users, n (%)   Non-clopidegrol and ASA/NSAIDs users, n (%)   Clopidegrol users with bleed, n (%)             Non-Clopidegrol users with bleed, n (%)              (Refs.)
  ------------------------ --------------------------------------------------- ------------------------------ ----------------------------------------- --------------------------------------------- ----------------------------------------------- ---------------------------------------------------- -----------------------
  Singh *et al*, 2010      RCC                                                 3,601                          142 (10.3%); 77 (54.0%); 14 (9.8%)        1,243 (89.7%); 398 (32.0%); 170 (13.7%)       3/142 (2.1%) Immediate; 5/142 (3.5%) Delayed    26/1,243 (2.1%) Immediate; 12/1,243 (1.0%) Delayed   ([@b6-etm-0-0-8597])
  Feagins *et al*, 2011    RCC^[b](#tfn2-etm-0-0-8597){ref-type="table-fn"}^   6,031                          118 (6.0%); 93 (78.8%); 9 (7.6%)          1,849 (94%); 515 (27.9%), 271 (14.7%)         N/A Immediate; 1/118 (0.8%) Delayed             N/A Immediate; 6/1,849 (0.3%) Delayed                ([@b8-etm-0-0-8597])
  Feagins *et al*, 2013    RCT                                                 1,732                          219 (42.4%); 192 (87.7%); 25 (11.5%)      297 (57.6%); 119 (40.1%); 40 (13.5%)          16/219 (7.3%) Immediate; 5/210 (2.4%) Delayed   14/297 (4.7%) Immediate; 0/286 Delayed               ([@b9-etm-0-0-8597])
  Chan *et al*, 2019       RCT^[a](#tfn1-etm-0-0-8597){ref-type="table-fn"}^   449                            106 (48.8%); 84 (79.2%); N/A              111 (52.2%); 86 (78.2%); N/A                  9/106 (8.5%) Immediate; 4/106 (3.8%) Delayed    6/110 (5.5%) Immediate; 4/110 (3.6%) Delayed         ([@b16-etm-0-0-8597])
  Grossman *et al*, 2010   RCC                                                 3,191                          70 (2.2%); N/A; N/A                       3,121 (97.8%); 627 (20.1%); 90 (2.9%)         3/70 (4.3%) Immediate; 3/70 (4.3%) Delayed      38/3121 (1.2%) Immediate 33/3121 (1.1%) Delayed      ([@b24-etm-0-0-8597])
  Total                                                                        15004                          655                                       6620                                          49                                              139                                                   

^a^RCT, randomized controlled trials;

^b^RCC, retrospective case-control; Immediate, immediate bleeding, Delayed, delayed bleeding; N/A, not available; ASA, aspirin; NSAIDS, non-steroidal anti-inflammatory drugs.

###### 

Quality assessment of randomized controlled trials using the Jadad Scale.

  Author, year            Randomization   Allocation concealment   Double blind   Random sequence generation   Dropouts                                             Jadad score   (Refs.)
  ----------------------- --------------- ------------------------ -------------- ---------------------------- ---------------------------------------------------- ------------- -----------------------
  Feagins *et al*, 2013   Yes             Yes                      Unclear        Yes                          9/10^[a](#tfn3-etm-0-0-8597){ref-type="table-fn"}^   3             ([@b9-etm-0-0-8597])
  Chan *et al*, 2019      Yes             Yes                      Yes            Yes                          No                                                   5             ([@b16-etm-0-0-8597])

^a^A total of 9 patient dropouts in the continued clopidogrel group; 10 patient dropouts in the non-clopidogrel group.

###### 

Quality assessment of randomized controlled trials by the Newcastle-Ottawa scale.

  Author, year             Selection   Comparability   Exposure or outcome   Total score   (Refs.)
  ------------------------ ----------- --------------- --------------------- ------------- -----------------------
  Feagins *et al*, 2011    +++         ++              \+                    6             ([@b8-etm-0-0-8597])
  Singh *et al*, 2010      +++         \+ +            \+                    6             ([@b6-etm-0-0-8597])
  Grossman *et al*, 2010   +++         \+ +            \+                    6             ([@b24-etm-0-0-8597])

[^1]: ^\*^Contributed equally

[^2]: *Abbreviations:* RCT, randomized controlled trials; PPB, post-polypectomy bleeding; RR, risk ratio; CI, confidence interval; CHD, coronary heart disease; AHA, American Heart Association; DAPT, dual antiplatelet therapy; NOS, Newcastle-Ottawa Scale; CRC, colorectal cancer
